BE854270A - Medicament anti-tumeur a base de compose du type lysolecithine - Google Patents

Medicament anti-tumeur a base de compose du type lysolecithine

Info

Publication number
BE854270A
BE854270A BE177280A BE177280A BE854270A BE 854270 A BE854270 A BE 854270A BE 177280 A BE177280 A BE 177280A BE 177280 A BE177280 A BE 177280A BE 854270 A BE854270 A BE 854270A
Authority
BE
Belgium
Prior art keywords
lysolecithin
type compound
product based
medicinal product
tumor medicinal
Prior art date
Application number
BE177280A
Other languages
English (en)
French (fr)
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of BE854270A publication Critical patent/BE854270A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE177280A 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine BE854270A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Publications (1)

Publication Number Publication Date
BE854270A true BE854270A (fr) 1977-11-04

Family

ID=5977045

Family Applications (1)

Application Number Title Priority Date Filing Date
BE177280A BE854270A (fr) 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine

Country Status (15)

Country Link
JP (1) JPS52134027A (enrdf_load_stackoverflow)
AU (1) AU517586B2 (enrdf_load_stackoverflow)
BE (1) BE854270A (enrdf_load_stackoverflow)
CA (1) CA1094455A (enrdf_load_stackoverflow)
DE (1) DE2619686C2 (enrdf_load_stackoverflow)
FR (1) FR2364656A1 (enrdf_load_stackoverflow)
GB (1) GB1583661A (enrdf_load_stackoverflow)
IE (1) IE44927B1 (enrdf_load_stackoverflow)
IL (1) IL51988A (enrdf_load_stackoverflow)
IT (1) IT1071329B (enrdf_load_stackoverflow)
LU (1) LU77248A1 (enrdf_load_stackoverflow)
NL (1) NL189672C (enrdf_load_stackoverflow)
NZ (1) NZ183981A (enrdf_load_stackoverflow)
SE (1) SE7705071L (enrdf_load_stackoverflow)
ZA (1) ZA772649B (enrdf_load_stackoverflow)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396311A (en) * 1977-01-29 1978-08-23 Toyama Chem Co Ltd Anti-cander drugs containing lysolecithins
JPS5528955A (en) * 1978-08-24 1980-02-29 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative, its salt, their preparation, and carcinostatic agent containing the same.
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4408052A (en) * 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4551532A (en) * 1980-05-08 1985-11-05 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity
EP0050327B1 (de) * 1980-10-21 1984-06-20 Roche Diagnostics GmbH Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPS5772914A (en) * 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
EP0061872B1 (en) * 1981-03-30 1985-08-07 Takeda Chemical Industries, Ltd. Ethyleneglycol derivatives, their production and use
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3131524A1 (de) * 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
DE3368933D1 (en) * 1982-09-21 1987-02-12 Fujisawa Pharmaceutical Co Phosphate derivatives, process for preparation thereof and pharmaceutical compositions of the same
US4710579A (en) * 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4761404A (en) * 1985-07-01 1988-08-02 Merck & Co., Inc. Phospholipid analogs useful as PAF synthesis inhibitors
EP0209239B1 (en) 1985-07-15 1989-03-01 Takeda Chemical Industries, Ltd. 2-alkanoyloxypropane derivatives, their production and use
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
DE3935580C2 (de) * 1989-10-25 1998-05-28 Medmark Pharma Gmbh Verwendung eines pharmazeutischen Wirkstoffes zur Behandlung von HIV-Infektionen
EP0581793A1 (en) * 1991-04-25 1994-02-09 University Of British Columbia Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents
ES2034885B1 (es) * 1991-07-10 1994-03-01 Menarini Lab Procedimiento para la preparacion de cetoalquilglicerofosfolipidos.
EP0785773B1 (en) * 1994-10-14 2001-01-03 The Liposome Company, Inc. Ether lipid liposomes and their therapeutic use
US5965159A (en) 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6135426A (en) * 1998-01-07 2000-10-24 Briggs And Stratton Corporation Priming system for internal combustion engines
AU2007316587B2 (en) 2006-11-10 2013-10-31 Cellprotect Patent Ag Methods and compositions for detecting receptor ligand mimetics
CN103816127A (zh) 2006-11-10 2014-05-28 阿尔法普托斯有限公司 含有三取代甘油化合物的口服剂型
WO2008074573A1 (en) * 2006-12-20 2008-06-26 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
RU2474427C2 (ru) * 2006-12-20 2013-02-10 Универзитетсклиникум Хамбург-Эппендорф Применение тризамещенных соединений глицерина для лечения гематологических злокачественных опухолей
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2033361C3 (de) * 1970-07-06 1980-02-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(13)-phosphorsäurecholinester und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
FR2364656B1 (enrdf_load_stackoverflow) 1980-03-07
IL51988A (en) 1981-05-20
AU517586B2 (en) 1981-08-13
JPS52134027A (en) 1977-11-09
NL189672B (nl) 1993-01-18
IL51988A0 (en) 1977-07-31
SE7705071L (sv) 1977-11-05
CA1094455A (en) 1981-01-27
IT1071329B (it) 1985-04-02
LU77248A1 (enrdf_load_stackoverflow) 1977-12-13
DE2619686A1 (de) 1977-11-24
NL7704723A (nl) 1977-11-08
IE44927B1 (en) 1982-05-19
NL189672C (nl) 1993-06-16
AU2481977A (en) 1978-11-09
JPS6146455B2 (enrdf_load_stackoverflow) 1986-10-14
NZ183981A (en) 1980-04-28
FR2364656A1 (fr) 1978-04-14
GB1583661A (en) 1981-01-28
DE2619686C2 (de) 1986-08-07
IE44927L (en) 1977-11-04
ZA772649B (en) 1978-04-26

Similar Documents

Publication Publication Date Title
BE854270A (fr) Medicament anti-tumeur a base de compose du type lysolecithine
BE839632A (fr) Medicament a base de sulfadiazine zincique
BE838938A (fr) Comprimes efferverscents d'edulcorants
SE7709359L (sv) Farmaceutisk doseringsform
BE883495A (fr) Medicament hypolipemiqude a base de carnitine
BE854925A (fr) Acides 12-azaprostanoiques utiles comme medicament
BE844532A (fr) Medicament a base d'un derive du benzothiadiazole
FR2307541A1 (fr) Medicament a base d'un polypeptide
DK408577A (da) Indgivelsessaet
BE862872A (fr) Medicament a base d'un compose heterocyclique bicyclique condense
JPS52128357A (en) Antiitumor drug
IT1081943B (it) Prodotto aerosolico
SE7705851L (sv) Forfarande for framstellning av en farmaceutisk komposition
FR2342067A1 (fr) Medicament a base d'un derive de la quinoleine
JPS5296750A (en) Oral drug compound
JPS5325579A (en) Pharmaceutical compound
BE853569A (nl) Medicinale preparaten
FR2347043A1 (fr) Medicament diuretique
BE811547A (fr) Medicament a base d'un derive de la 7h-benzocycloheptene-7-one
AU517608B2 (en) Medicaments
BE801014A (fr) Medicament a base d'(hydroxy-2 indanyl-2)1 propylamine
JPS5338620A (en) Isomalin antiimold drug
ZA777335B (en) Pharmaceutical compounds
BE823487A (fr) Medicament a base de vincamine
FR2337555A1 (fr) Medicament a base de 1,3-bis(2-tetrahydrofuryl)-5-fluoro-uracile

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENS

Effective date: 19970504